- Home
- VGZ vs MCRB Comparison
VGZ vs MCRB Comparison
Compare VGZ & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGZ
- MCRB
- Stock Information
- Founded
- VGZ 1983
- MCRB 2010
- Country
- VGZ United States
- MCRB United States
- Employees
- VGZ N/A
- MCRB N/A
- Industry
- VGZ
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- VGZ
- MCRB Health Care
- Exchange
- VGZ Nasdaq
- MCRB Nasdaq
- Market Cap
- VGZ 171.5M
- MCRB 144.6M
- IPO Year
- VGZ N/A
- MCRB 2015
- Fundamental
- Price
- VGZ $2.23
- MCRB $20.39
- Analyst Decision
- VGZ Strong Buy
- MCRB Hold
- Analyst Count
- VGZ 1
- MCRB 4
- Target Price
- VGZ $3.00
- MCRB $14.33
- AVG Volume (30 Days)
- VGZ 2.2M
- MCRB 129.8K
- Earning Date
- VGZ 10-23-2025
- MCRB 11-12-2025
- Dividend Yield
- VGZ N/A
- MCRB N/A
- EPS Growth
- VGZ N/A
- MCRB N/A
- EPS
- VGZ N/A
- MCRB 10.22
- Revenue
- VGZ N/A
- MCRB N/A
- Revenue This Year
- VGZ N/A
- MCRB N/A
- Revenue Next Year
- VGZ N/A
- MCRB N/A
- P/E Ratio
- VGZ N/A
- MCRB $1.89
- Revenue Growth
- VGZ N/A
- MCRB N/A
- 52 Week Low
- VGZ $0.47
- MCRB $6.53
- 52 Week High
- VGZ $2.46
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- VGZ 62.50
- MCRB 57.52
- Support Level
- VGZ $2.11
- MCRB $19.17
- Resistance Level
- VGZ $2.27
- MCRB $21.50
- Average True Range (ATR)
- VGZ 0.13
- MCRB 1.27
- MACD
- VGZ -0.03
- MCRB -0.07
- Stochastic Oscillator
- VGZ 44.71
- MCRB 58.32
About VGZ Vista Gold Corp
Vista Gold Corp is a gold mining company. It is engaged in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects. The company evaluate, acquire, explore and advance gold exploration and potential development projects for gold production or value adding strategic transactions. The Company has one reportable segment: Australia. The Australia segment conducts exploration, development, care and maintenance activities at Vista's asset, the Mt Todd gold project in Northern Territory, Australia.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.